Financial Performance - Net revenues for Q1 2025 were RMB28.8 billion (US$4.0 billion), a 7.4% increase year-over-year[4] - Net revenues from games and related services were RMB24.0 billion (US$3.3 billion), reflecting a 12.1% increase compared to Q1 2024[4] - Youdao's net revenues decreased by 6.7% year-over-year to RMB1.3 billion (US$178.9 million)[4] - NetEase Cloud Music reported net revenues of RMB1.9 billion (US$256.1 million), down 8.4% from the same quarter last year[4] - NetEase reported net revenues of RMB 28,828,545 (approximately USD 3,972,680) for the three months ended March 31, 2025, representing an increase from RMB 26,747,811 in the previous quarter[43] - Total net revenues for the same period reached RMB 28,828,545 (USD 3,972,680), up 7.7% from RMB 26,747,811 in the previous quarter[46] Profitability - Gross profit for Q1 2025 was RMB18.5 billion (US$2.5 billion), an increase of 8.6% year-over-year[4] - The gross profit for the same period was RMB 18,479,406, up from RMB 16,272,341 in the previous quarter, indicating a gross margin improvement[43] - Net income attributable to shareholders was RMB10.3 billion (US$1.4 billion), up from RMB7.6 billion in Q1 2024[19] - Net income attributable to the Company's shareholders for the three months ended March 31, 2025, was RMB 10,301,157 (approximately USD 1,419,537), compared to RMB 8,766,479 in the previous quarter, reflecting a growth of 17.5%[43] - Non-GAAP net income attributable to shareholders was RMB11.2 billion (US$1.5 billion), a 31.6% increase year-over-year[22] - NetEase reported a net income of RMB 10,546,771 (USD 1,453,384) for the three months ended March 31, 2025, representing a 18.3% increase from RMB 8,918,953 in the previous quarter[45] - Non-GAAP net income attributable to the company's shareholders for the quarter was RMB 11,236,727 (USD 1,548,462), up from RMB 9,681,968 in the previous quarter[50] Expenses and Costs - Total operating expenses decreased by 14.4% year-over-year to RMB8.0 billion (US$1.1 billion)[4] - Research and development expenses for the three months ended March 31, 2025, were RMB 4,386,313, showing a slight decrease from RMB 4,469,868 in the previous quarter[43] - The total cost of revenues for the three months ended March 31, 2025, was RMB 10,349,139 (USD 1,426,149), a decrease from RMB 10,475,470 in the previous quarter[46] - The share-based compensation cost for the three months ended March 31, 2025, was RMB 951,872 (USD 131,170), showing a slight increase from RMB 931,444 in the previous quarter[49] Cash and Assets - As of March 31, 2025, the company's net cash totaled RMB137.0 billion (US$18.9 billion), an increase from RMB131.5 billion at the end of 2024[23] - The total current assets increased to RMB 157,670,710 as of March 31, 2025, from RMB 153,324,656 as of December 31, 2024[42] - Cash and cash equivalents decreased to RMB 41,748,614 as of March 31, 2025, from RMB 51,383,310 as of December 31, 2024[42] - Net cash provided by operating activities was RMB 12,106,652 (USD 1,668,341) for the three months ended March 31, 2025, down from RMB 13,012,200 in the previous quarter[45] - The company reported a total cash, cash equivalents, and restricted cash balance of RMB 45,395,483 (USD 6,255,665) at the end of the period[45] - NetEase's total assets reached RMB 200,858,132 as of March 31, 2025, up from RMB 195,991,550 as of December 31, 2024[42] - Total liabilities decreased slightly to RMB 52,988,888 as of March 31, 2025, from RMB 53,497,412 as of December 31, 2024[42] Business Development - The company maintained a strong game pipeline with multiple new titles under development, including MARVEL Mystic Mayhem and Destiny: Rising[7] - The company emphasized the importance of non-GAAP financial measures in assessing its operating performance, excluding share-based compensation expenses[38] - The company experienced a significant decrease in cash used in investing activities, totaling RMB (12,841,002) (USD (1,769,538)) for the quarter, compared to RMB 20,628,527 in the previous quarter[45] - The gross profit for the games and related value-added services segment was RMB 16,552,745 (USD 2,281,029), reflecting a 16.8% increase compared to RMB 14,166,848 in the previous quarter[46]

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______, 20___, to _____, 20___. Commission File Number 001-41272 HeartCore Enterprises, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 46-0920988 | | --- | --- | | (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | | 1280 Rancho Conejo Boulevard | | | Thousand Oaks, CA | 91320 | | (Address of Principal Executive Offices) | (Zip Code) | | Registrant's Teleph ...

Exhibit 99.1 Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives • Atara has paused development of its CAR T progra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39761 ONDAS HOLDINGS INC. (Exact name of registrant as specified in its charter) incorporation or organization) ...

____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40034 _________________ ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________ FORM 10-Q ____________________________________ (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40034 _________________ ...

Exhibit 99.1 Cash runway expected to fund operations through Q3 2025 LA JOLLA, CA, May 15, 2025 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the quarter ended March 31, 2025 and provided a corporate update. "We continue to make very encouraging progress with our ongoing Phase 2a trial ...

Exhibit 99.1 GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI- 0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) and over two-thirds enrollment completed for the overall trial Cash runway e ...